JO3183B1 - طرق لمعالجة أمراض المناعة الذاتية مضادات dll4 - Google Patents

طرق لمعالجة أمراض المناعة الذاتية مضادات dll4

Info

Publication number
JO3183B1
JO3183B1 JOP/2011/0021A JOP20110021A JO3183B1 JO 3183 B1 JO3183 B1 JO 3183B1 JO P20110021 A JOP20110021 A JO P20110021A JO 3183 B1 JO3183 B1 JO 3183B1
Authority
JO
Jordan
Prior art keywords
dii4
methods
diseases
disorders
disease
Prior art date
Application number
JOP/2011/0021A
Other languages
English (en)
Inventor
Skokos Dimitris
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Application granted granted Critical
Publication of JO3183B1 publication Critical patent/JO3183B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

يوفر الاختراع الحالي أساليب لعلاج مرض أو اضطراب، تكون فيه الزيادة في عدد خلايا (تريغ) T التنظيمية مفيدا، عن طريق إعطاء جرعة دوائية لمستهدف يعاني من ذلك المرض أو الاضطراب بجرعة علاجية من ضاد DII4 التي تقيد مسارات إشارة ثلمة-DII4، بذلك يزداد عدد خلايا تريغ. تشمل الأمراض أو الاضطرابات القابلة للعلاج عن طريق أساليب من هذا الاختراع مثل التصلب المتعدد (MS)، داء السكري، وما شابهها. يشمل الضاد المناسب DII4 لهذا الاختراع الأجسام المضادة أو جزيئات من الأجسام المضادة التي تربط بشكل خاص DII4 وتقيد تفاعلات ثلمة-DII4، والمجال الخارجي من DII4، وما شابهها. يوفر الاختراع أيضا أساليب لمنع حدوث أو عودة حدوث هكذا أمراض أو اضطرابات في مستهدف تعرض سابقا أو لديه قابلية للتعرض أو تطوير هكذا أمراض أو اضطرابات. علاوة على ذلك، فإن الأساليب من هذا الاختراع تكون مفيدة لمنع أو لعلاج رفض زراعة الأعضاء أو داء الطعم حيال الثوى.
JOP/2011/0021A 2010-01-29 2011-01-23 طرق لمعالجة أمراض المناعة الذاتية مضادات dll4 JO3183B1 (ar)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29980110P 2010-01-29 2010-01-29
US36168710P 2010-07-06 2010-07-06
US38869710P 2010-10-01 2010-10-01

Publications (1)

Publication Number Publication Date
JO3183B1 true JO3183B1 (ar) 2018-03-08

Family

ID=43925413

Family Applications (2)

Application Number Title Priority Date Filing Date
JOP/2011/0021A JO3183B1 (ar) 2010-01-29 2011-01-23 طرق لمعالجة أمراض المناعة الذاتية مضادات dll4
JOP/2017/0065A JO3242B1 (ar) 2010-01-29 2017-03-19 طرق علاج داء السكري بمستضادات dll4

Family Applications After (1)

Application Number Title Priority Date Filing Date
JOP/2017/0065A JO3242B1 (ar) 2010-01-29 2017-03-19 طرق علاج داء السكري بمستضادات dll4

Country Status (29)

Country Link
US (3) US8889133B2 (ar)
EP (2) EP2528945B1 (ar)
JP (2) JP5997613B2 (ar)
KR (2) KR101797918B1 (ar)
CN (2) CN102947336B (ar)
AR (1) AR080026A1 (ar)
AU (2) AU2011210771B2 (ar)
BR (2) BR112012018766A2 (ar)
CA (2) CA2787394C (ar)
CY (2) CY1118223T1 (ar)
DK (2) DK2528946T3 (ar)
ES (2) ES2609663T3 (ar)
HR (2) HRP20170130T1 (ar)
HU (2) HUE032985T2 (ar)
IL (2) IL220889A (ar)
JO (2) JO3183B1 (ar)
LT (2) LT2528945T (ar)
MX (2) MX343553B (ar)
MY (2) MY156538A (ar)
PL (2) PL2528946T3 (ar)
PT (2) PT2528946T (ar)
RS (2) RS55595B1 (ar)
RU (2) RU2587624C2 (ar)
SG (4) SG10201500404QA (ar)
SI (2) SI2528945T1 (ar)
SM (3) SMT201700021T1 (ar)
TW (2) TWI564019B (ar)
UY (1) UY33206A (ar)
WO (2) WO2011094467A2 (ar)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2448979C2 (ru) * 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
CA2771575A1 (en) 2009-08-29 2011-03-03 Abbott Laboratories Therapeutic dll4 binding proteins
EP3485908B1 (en) 2009-10-16 2021-08-18 Mereo BioPharma 5, Inc. Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents
JO3183B1 (ar) 2010-01-29 2018-03-08 Regeneron Pharma طرق لمعالجة أمراض المناعة الذاتية مضادات dll4
WO2011109298A2 (en) 2010-03-02 2011-09-09 Abbott Laboratories Therapeutic dll4 binding proteins
TWI583699B (zh) 2011-09-23 2017-05-21 安可美德藥物股份有限公司 Ｖｅｇｆ／ｄｌｌ４結合劑類及彼等之用途
KR101535341B1 (ko) 2012-07-02 2015-07-13 한화케미칼 주식회사 Dll4에 특이적으로 결합하는 신규한 단일클론항체 및 이의 용도
PE20151179A1 (es) 2012-11-01 2015-09-12 Abbvie Inc Inmunoglobulinas de dominio variable dual anti-vegf/dll4 y usos de las mismas
TW201438736A (zh) * 2012-11-14 2014-10-16 Regeneron Pharma 以ｄｌｌ４拮抗劑治療卵巢癌之方法
CA2917402C (en) 2013-07-09 2019-10-22 Hanwha Chemical Corporation Novel dual-targeting protein binding specifically to dll4 and vegf and use thereof
WO2015057968A2 (en) * 2013-10-17 2015-04-23 The General Hospital Corporation Methods of identifying subjects responsive to treatment for an autoimmune disease and compositions for treating the same
CA2944811C (en) * 2014-04-08 2022-06-21 Urs Christen Combination therapy for the treatment of autoimmune diseases
EP3212233B1 (en) 2014-10-31 2020-06-24 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
US11339213B2 (en) 2015-09-23 2022-05-24 Mereo Biopharma 5, Inc. Methods and compositions for treatment of cancer
US11446262B2 (en) 2018-11-29 2022-09-20 Debora Zucco Sassi Yonezawa Siviglia Neuroquiescence—a treatment for neurodevelopmental and neurodegenerative bioelectrical dysregulation and demyelination
EP3886856A4 (en) 2018-11-29 2022-01-19 Zucco Sassi Yonezawa Siviglia, Debora METHOD FOR TREATING OR PREVENTING SEIZURES ASSOCIATED WITH AN EPILEPTIC DISORDER
US20240287173A1 (en) * 2021-03-30 2024-08-29 National University Corporation Kumamoto University Therapeutic agent for muscular atrophy
WO2023159166A1 (en) * 2022-02-18 2023-08-24 H. Lee Moffitt Cancer Center And Research Institute, Inc. Single-domain antibodies (nanobodies) targeting the notch ligand dll4 and methods of their use
US20240148789A1 (en) * 2022-07-15 2024-05-09 The University Of Toledo Synergistic Inhibition of eIF5A and Notch Signaling
WO2025212726A2 (en) 2024-04-04 2025-10-09 Compass Therapeutics, Inc. Combination of antibodies targeting dll4/vegf and cd137 agonists or anti-pd1/anti-pd-l1 antibodies for the treatment of cancer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
AU2003248558B8 (en) * 2002-05-21 2009-07-09 Gilead Sciences, Inc. Method of treating diabetes
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
US20060134121A1 (en) 2004-10-29 2006-06-22 Gavin Thurston DII4 antagonists, assays, and therapeutic methods thereof
PL1962895T3 (pl) 2005-12-16 2013-06-28 Regeneron Pharma Terapeutyczne zastosowanie antagonisty dii4 oraz inhibitora vegf do inhibicji wzrostu nowotworów
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
JP2009539870A (ja) 2006-06-06 2009-11-19 ジェネンテック・インコーポレーテッド 血管発生の調節ための組成物および方法
AU2007319672B2 (en) * 2006-06-06 2011-06-30 Genentech, Inc. Anti-DLL4 antibodies and methods using same
NZ574794A (en) 2006-08-07 2011-06-30 Regeneron Pharma Use of delta-like ligand 4 (DLL4) antagonists for treating eye vascular and ischemic injury
HRP20160082T1 (hr) 2006-09-29 2016-02-26 Oncomed Pharmaceuticals, Inc. Sastavi i postupci za dijagnosticiranje i lijeäśenje raka
RU2448979C2 (ru) * 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
CA2771575A1 (en) 2009-08-29 2011-03-03 Abbott Laboratories Therapeutic dll4 binding proteins
JO3183B1 (ar) 2010-01-29 2018-03-08 Regeneron Pharma طرق لمعالجة أمراض المناعة الذاتية مضادات dll4

Also Published As

Publication number Publication date
DK2528946T3 (en) 2017-02-20
EP2528945A2 (en) 2012-12-05
MY156353A (en) 2016-02-15
HUE031432T2 (en) 2017-07-28
US20110189200A1 (en) 2011-08-04
ES2605430T3 (es) 2017-03-14
LT2528946T (lt) 2017-01-25
IL220889A (en) 2017-07-31
PL2528945T3 (pl) 2017-02-28
SI2528946T1 (sl) 2017-01-31
CA2787615C (en) 2019-01-15
IL220887A (en) 2017-07-31
CN102947336A (zh) 2013-02-27
WO2011094467A2 (en) 2011-08-04
JP2013518122A (ja) 2013-05-20
US20110189176A1 (en) 2011-08-04
RU2587624C2 (ru) 2016-06-20
TWI564019B (zh) 2017-01-01
JO3242B1 (ar) 2018-03-08
RS55595B1 (sr) 2017-06-30
CA2787615A1 (en) 2011-08-04
DK2528945T3 (en) 2017-02-06
MX343553B (es) 2016-11-10
MX343555B (es) 2016-11-10
US8765125B2 (en) 2014-07-01
MX2012008740A (es) 2012-08-31
HRP20170249T1 (hr) 2017-04-07
IL220889A0 (en) 2012-09-24
SMT201600412B (it) 2017-01-10
CY1118223T1 (el) 2017-06-28
ES2609663T3 (es) 2017-04-21
BR112012018820A2 (pt) 2017-01-10
US8889133B2 (en) 2014-11-18
BR112012018820A8 (pt) 2018-03-13
SG10201500416RA (en) 2015-04-29
AU2011210773B2 (en) 2015-11-19
CA2787394A1 (en) 2011-08-04
CY1118551T1 (el) 2017-07-12
KR101797918B1 (ko) 2017-11-15
KR20120123745A (ko) 2012-11-09
PL2528946T3 (pl) 2017-04-28
JP5883801B2 (ja) 2016-03-15
BR112012018766A2 (pt) 2017-01-10
TW201615207A (zh) 2016-05-01
RU2012136817A (ru) 2014-03-10
LT2528945T (lt) 2017-01-25
US20140255429A1 (en) 2014-09-11
TW201136601A (en) 2011-11-01
AU2011210771A1 (en) 2012-08-23
RS55715B1 (sr) 2017-07-31
PT2528946T (pt) 2016-12-14
KR101832118B1 (ko) 2018-02-26
SG182527A1 (en) 2012-08-30
HRP20170130T1 (hr) 2017-03-24
SI2528945T1 (sl) 2017-01-31
MX2012008638A (es) 2012-12-05
SMT201700021T1 (it) 2017-03-08
SG10201500404QA (en) 2015-03-30
EP2528946B1 (en) 2016-11-16
JP5997613B2 (ja) 2016-09-28
JP2013518123A (ja) 2013-05-20
AU2011210771B2 (en) 2015-12-10
MY156538A (en) 2016-02-26
AU2011210773A1 (en) 2012-08-23
TWI600433B (zh) 2017-10-01
WO2011094465A1 (en) 2011-08-04
KR20130008017A (ko) 2013-01-21
EP2528946A1 (en) 2012-12-05
CN102947336B (zh) 2015-12-02
CN102884081A (zh) 2013-01-16
CA2787394C (en) 2019-01-08
SMT201700021B (it) 2017-03-08
WO2011094467A3 (en) 2011-12-22
UY33206A (es) 2011-08-31
EP2528945B1 (en) 2016-10-26
HUE032985T2 (en) 2017-11-28
AR080026A1 (es) 2012-03-07
SG182528A1 (en) 2012-08-30
RU2587620C2 (ru) 2016-06-20
PT2528945T (pt) 2016-12-14
RU2012136816A (ru) 2014-03-10
WO2011094465A4 (en) 2011-09-22

Similar Documents

Publication Publication Date Title
Anfray et al. Intratumoral combination therapy with poly (I: C) and resiquimod synergistically triggers tumor-associated macrophages for effective systemic antitumoral immunity
Jordan et al. A novel targeted approach to the treatment of hemophagocytic lymphohistiocytosis (HLH) with an anti-interferon gamma (IFNγ) monoclonal antibody (mAb), NI-0501: first results from a pilot phase 2 study in children with primary HLH
Sun et al. Macrophage phenotype in liver injury and repair
Walsh et al. Proteasome inhibitor-based therapy for antibody-mediated rejection
AU2017278220B2 (en) Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy
EA201490957A1 (ru) Лечение гематологических злокачественных заболеваний с помощью анти-cxcr4 антитела
AR080026A1 (es) Metodos de tratamiento de enfermedades autoinmunitarias con antagonistas del ligando 4 similar a delta (dll4)
EA033400B1 (ru) Антитело против cd3 и его применение
EA201892184A1 (ru) Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора
TW200716743A (en) Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
MY160892A (en) Antibodies to ccr2
MX348577B (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
EA201190043A1 (ru) Имидазопиразиновые ингибиторы syk
EA201591191A1 (ru) Антитела против ntb-a и связанные с ними композиции и способы
EA201490622A1 (ru) Агенты, связывающие фактор роста эндотелия сосудов (vegf)/дельта-подобный лиганд (dll4), и их применение
EA201100779A1 (ru) Композиции антител к cxcr1 и способы их применения
NZ612175A (en) Anti ccr4 antibodies and uses thereof
EA201991704A3 (ru) Моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
CN102573500A (zh) 巨噬细胞相关疾病的治疗
Liu et al. Curcumin reduces brain-infiltrating T lymphocytes after intracerebral hemorrhage in mice
Cong et al. Blocking two-pore domain potassium channel TREK-1 inhibits the activation of A1-like reactive astrocyte through the NF-κB signaling pathway in a rat model of major depressive disorder
RU2014117952A (ru) Антитела против sema4a человека, используемые для лечения заболевания
EA202192488A1 (ru) Антитела против tsg-6 и их применения
Wang et al. Cytokine Storm Induction Linked to Multi‐Organ Failure in Fatal Jellyfish Stings
Yang et al. Immunotherapies for aging and age-related diseases: Advances, pitfalls, and prospects